Background and Purpose-The Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET) was a prospective, randomized, double-blinded, placebo-controlled, phase II trial of alteplase between 3 and 6 hours after stroke onset. The primary outcome of infarct growth attenuation on MRI with alteplase in mismatch patients was negative when mismatch volumes were assessed volumetrically, without coregistration, which underestimates mismatch volumes. We hypothesized that assessing the extent of mismatch by coregistration of perfusion and diffusion MRI maps may more accurately allow the effects of alteplase vs placebo to be evaluated. Methods-Patients were classified as having mismatch if perfusion-weighted imaging divided by coregistered diffusionweighted imaging volume ratio was Ͼ1.2 and total coregistered mismatch volume was Ն10 mL. The primary outcome was a comparison of infarct growth in alteplase vs placebo patients with coregistered mismatch. Results-Of 99 patients with baseline diffusion-weighted imaging and perfusion-weighted imaging, coregistration of both images was possible in 95 patients. Coregistered mismatch was present in 93% (88/95) compared to 85% (81/95) with standard volumetric mismatch. In the coregistered mismatch patients, of whom 45 received alteplase and 43 received placebo, the primary outcome measure of geometric mean infarct growth was significantly attenuated by a ratio of 0.58 with alteplase compared to placebo (1.02 vs 1.77; 95% CI, 0.33-0.99; Pϭ0.0459). Conclusions-When using coregistration techniques to determine the presence of mismatch at study entry, alteplase significantly attenuated infarct growth. This highlights the necessity for a randomized, placebo-controlled, phase III clinical trial of alteplase using penumbral selection beyond 3 hours. (Stroke. 2011;42:59-64.)
R eperfusion therapies including intravenous thrombolysis with recombinant tissue plasminogen activator are based on the premise that ischemic penumbral tissue is at risk for infarction but has the potential to be salvaged by reperfusion. 1 With the advent of MRI techniques, the mismatch concept defined by the perfusion-weighted imaging (PWI) lesion exceeding the diffusion-weighted imaging (DWI) lesion was postulated as a penumbral marker. 2 Since then, MR PWI/ DWI has become a widely used imaging research technique in the assessment of acute stroke patients. 3 Mismatch volume (MV) is conventionally calculated using a volumetric method in which the DWI lesion volume is simply subtracted from the PWI volume. 2 This method assumes that ischemic core represented by the DWI lesion is surrounded by a hypoperfused area defined by the PWI lesion. 4 However, the region of hypoperfusion fluctuates in the hours after stroke onset attributable to processes such as spontaneous reperfusion and changes in collateral blood flow. 5 Early reperfusion of the infarct core may result in a component of the DWI lesion lying outside the PWI lesion. 6 Coregistration of DWI and PWI images allows a more precise estimate of these spatial relationships, with simple volumetric analysis consistently underestimating the mismatch volume when compared to the coregistration method. 7 The Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET) was a phase II, prospective, randomized, doubleblinded, placebo-controlled, multinational trial of 101 patients treated between 3 and 6 hours after stroke onset. 8 Importantly, the primary hypothesis was that patients with mismatch (defined by the standard volumetric method) who received alteplase would have attenuation of infarct growth seen on MRI. Although there was a trend toward attenuation of infarct growth, this did not reach statistical significance. Given that the mismatch assessment in EPITHET by the volumetric method may have underestimated the mismatch volume and, hence, the target population in whom the primary hypothesis was tested, we reanalyzed the dataset using coregistration of DWI/PWI images at baseline. We hypothesized that this may have increased the number of patients with eligible mismatch and that this, in turn, may have influenced the effects of alteplase on attenuation of infarct growth.
Patients and Methods

Imaging Protocol
The study design of EPITHET, including patient eligibility, treatment allocation, and imaging protocol, has been previously reported. 8 Briefly, patients with acute hemispheric ischemic stroke who presented 3 to 6 hours after symptom onset were assigned to intravenous alteplase or placebo and had DWI, PWI, and MRA sequences with 1.5-T echoplanar-equipped MRI scanners before treatment and again at days 3 to 5. At day 90, T2-weighted images were obtained to measure final infarct volume.
Imaging Analysis
Baseline DWI was registered to the baseline PWI using MINC software (The McConnell Brain Imaging Centre) by 1 investigator (Y.N.) blinded to treatment assignment but not to time point. First, automatic registration was applied to register baseline DWI to the PWI frame. Second, manual landmark-based registration was used to initialize another automatic registration in cases in which automatic coregistration failed on the first attempt. The quality of coregistration was reviewed by a second investigator (S.C.).
Using these coregistration techniques, the baseline DWI lesion was divided into 2 regions: DWI within and DWI outside of the PWI volume ( Figure 1 ). Regions of interest on DWI and T2-weighted images, Tmax map, and MRA ratings were unaltered from the original trial. Similarly, hypoperfusion volumes were defined using a Tmax delay of Ն2 seconds as previously described. For patients who died or who could not be studied at day 90, the last results at days 3 to 5 were carried forward as a measure of imaging outcome.
Definitions
All definitions were as in the main EPITHET study except for the addition of coregistered mismatch (Table 1) . 8 
Outcome Measures
The primary outcome measure was infarct growth attenuation in coregistered mismatch patients between alteplase and placebo, primarily analyzed by geometric mean and secondarily by relative growth, absolute growth, and difference in cube root lesion volumes. Secondary end points included reperfusion, clinical outcomes, recanalization, and symptomatic intracerebral hemorrhage.
Statistical Analysis
Statistical analyses were performed using Stata/IC 10 (StataCorp). The comparisons between volumetric and coregistration methods were made with Wilcoxon signed-rank test for continuous variables and with McNemar exact test for categorical variables. The agreement between the original DWI volumes and the coregistered DWI volumes was assessed by Lin's concordance coefficient and intraclass correlation coefficient. As per the original protocol of EPITHET, the difference in means of log-relative growth between patients treated Figure 1 . A, Coregistration of perfusionweighted imaging (PWI) and diffusionweighted imaging (DWI) allows the DWI lesion to be divided into 2 regions: DWI within (wDWI; yellow) and DWI lying outside the PWI lesion (oDWI; red). Using the volumetric technique, the mismatch volume (MV) is PWIϪ(wDWIϩoDWI), whereas the coregistered MV (green) is defined as PWIϪwDWI. An 82-year-old woman with baseline MRI performed 325 minutes after stroke onset. The baseline DWI lesion volume was 65.3 mL (B) and PWI lesion volume was 68.8 mL (C; green areas indicate PWI abnormalities of Tmax 2 seconds or more). In EPITHET using the volumetric technique, she was classified as having no mismatch (3.5 mL); however, while coregistered (D), she was classified as having mismatch (26.2 mL; wDWI in yellow, oDWI in red, and coregistered mismatch areas in green).
with alteplase and with placebo was tested by t test. The 2-sample Wilcoxon rank-sum test was used for the comparison of relative growth, absolute growth, and the difference of cube root transformed volume change. Hodges-Lehman shift parameter was used to estimate effect sizes for the comparisons when the Wilcoxon rank-sum test was used. Fisher exact test was used to compare patients treated with alteplase and with placebo in respect to the presence or absence of growth (any), reperfusion, and recanalization status, as well as for clinical outcomes. As per the original EPITHET analysis, no adjustments for multiple comparisons were made.
Results
Ninety-nine of 101 patients enrolled in EPITHET had baseline DWI and PWI and were included in this study. Automatic coregistration of baseline DWI and PWI succeeded in 95 of 99 patients, with 5 patients requiring initialization by manual landmarks. Coregistration failed in 4 (4%) patients because of artifact (3 had severe ghost artifacts of PWI and 1 had DWI motion artifacts), and these patients were excluded from subsequent analysis. Table 2 shows baseline imaging variables for the 95 patients. Transformation of DWI into PWI space during the coregistration process resulted in baseline DWI volume increasing slightly from 20 mL (range, 0 -197) to 21 mL (range, 0 -204), and the agreement on the DWI volumes between original and after coregistration was confirmed by both intraclass correlation coefficient of 1.00 (95% CI, 0.98 -1.00) and Lin concordance coefficient of 0.996 (0.995-0.998). After coregistration, median baseline DWI within and DWI outside the PWI lesion volumes were 13 mL (range, 0 -152) and 5 mL (range, 0 -119), respectively. Median baseline coregistered MV was significantly larger than baseline volumetric MV (128 mL vs 118 mL), with median difference of 5 mL (interquartile range, 3-12; 95% CI, 4 -6; PϽ0.0001). Because 7 patients with no mismatch by the volumetric method had mismatch by the coregistration method ( Figure 1B) , the prevalence of mismatch increased from 85% (81/95) by the volumetric method to 93% (88/95) by the coregistration method (Pϭ0.0156). Figure 2 shows the study profile and Table 3 shows baseline characteristics for mismatch patients with valid imaging outcomes. Of the 101 enrolled patients, 91 patients had baseline PWI and DWI with a day-90 T2-weighted image or with a surrogate day-3 to day-5 DWI for the final lesion. Because of coregistration failure in 4 patients (2 each in the alteplase and placebo groups), 87 patients were assessed for mismatch between PWI and DWI and 80 had mismatch (38 received alteplase and 42 received placebo). Baseline variables of patients with mismatch did not significantly differ (PՆ0.1) between alteplase and placebo groups (Table 3) , and no statistical correction was needed.
For the primary outcome measure using the originally prespecified analytic method (geometric mean growth), the coregistered mismatch patients showed significant infarct growth attenuation with alteplase compared to placebo (1.02 vs 1.77; ratio, 0.58; 95% CI, 0.33-0.99; Pϭ0.0459; Table 4 ). When the geometric mean growth was compared among the volumetric mismatch patients without coregistration, infarct growth attenuation did not differ between the treatment groups (1.06 vs 1.79; ratio, 0.59; 95% CI, 0.32-1.06; Pϭ0.0779). This was confirmed by significant attenuation in infarct growth by the secondary analytical methods: relative growth (Pϭ0.0139), absolute growth (Pϭ0.0332), and difference in cube root lesion volume (Pϭ0.0204). Further additional analytical methods including the proportion of patients who had any growth (Pϭ0.0216), ratio of geometric mean (Pϭ0.0113), and median relative growth (Pϭ0.0038) Any growth: relative growth Ͼ0%
Malignant profile: DWI volume and/or PWI volume with Tmax Ն8 seconds Ն100 mL Reperfusion: Ͼ90% reduction between baseline and day-3 PWI volumes Recanalization: improvement from baseline to day 3 to 5 in arterial obstruction by Ն2 points, based on an adaptation of the thrombolysis in myocardial infarction grading on MRA (0ϭcomplete occlusion, 1ϭsevere stenosis, 2ϭmild to moderate stenosis, and 3ϭnormal arterial caliber) Symptomatic ICH: ICH with significant clinical deterioration of Ն4 NIHSS points within 36 hours of treatment and parenchymal hemorrhage of grade 2 on CT (blood clots in Ͼ30% of the infarcted area with substantial space-occupying effect) adjudicated by a blinded committee (SITS-MOST definition) 9 Good neurological outcome: NIHSS at day 90 of 0 or 1 or improvement Ն8 from baseline Good functional outcome: modified Rankin scale at day 90 of 0 to 2 DWI indicates diffusion-weighted imaging; ICH, intracerebral hemorrhage; PWI, perfusion-weighted imaging; wDWI, diffusion-weighted imaging within the perfusion-weighted imaging lesion. DWI indicates diffusion-weighted imaging; PWI, perfusion-weighted imaging; wDWI, diffusion-weighted imaging within the perfusion-weighted imaging lesion.
Data are median (range) or N (%) of patients.
in patients with a baseline lesion of Ͼ5 mL (33 patients in the alteplase group and 36 in the placebo group) also showed a positive effect of alteplase compared to placebo. For secondary outcome measures, 76 of the 88 coregistered mismatch patients had a valid PWI volume at days 3 to 5 to assess reperfusion, and all 88 had assessment of clinical outcome (Tables 4 and the online-only supplemental Table, available at http://stroke.ahajournals.org). Both the incidence of reperfusion (Ն90%) and the median percentage of reperfusion were significantly higher in patients with coregistered mismatch who received alteplase. Reperfusion was significantly associated with infarct growth attenuation, good neurological outcome, and good functional outcome in patients with coregistered mismatch. As with the original EPITHET analysis, which was not powered for a clinical outcome, the difference in good neurological and functional outcomes between the alteplase and placebo groups was not significant in patients with coregistered mismatch. Recanalization could be assessed with adequate MRA scans in 43 patients with coregistered mismatch, and it occurred in 27 (63%) of these patients (Table 4 ). The proportion of recanalization did not differ between treatment arms.
Symptomatic intracerebral hemorrhage was seen in 8.0% (4/50) of patients treated with alteplase. All patients had mismatch by the coregistration method, whereas 3 out of 4 had mismatch by the volumetric method. Median baseline DWI volume did not differ between patients with symptomatic intracerebral hemorrhage (43 mL; interquartile range, 31-101) and those without symptomatic intracerebral hemorrhage (15 mL; interquartile range, 7-37; Pϭ0.058).
Primary outcome could be assessed in 7 patients without coregistered mismatch. Infarct growth did not differ significantly between the alteplase and placebo groups (geometric mean growth 0.93 vs 1.03; ratio, 0.91; 95% CI, 0.31-2.66; Pϭ0.8283). Between mismatch and nonmismatch patients in the alteplase group, infarct growth, reperfusion rate, and clinical outcomes did not differ significantly.
Discussion
The efficacy analysis in EPITHET, although negative on the prespecified primary outcome, provided strong support for further investigation of the use of PWI/DWI mismatch in the identification of favorable reperfusion outcomes with alteplase. By applying the coregistration method to assess MV DWI indicates diffusion-weighted imaging; PWI, perfusion-weighted imaging. Data are mean (SD), median (range), or N (%) of patients. *DWI volume Ն100 mL, PWI volume Ն100 mL, or both, with Tmax delay Ն8 sec.
at study entry, we found that the prevalence of mismatch patients was increased and resulted in a positive outcome of EPITHET for the primary end point of infarct growth attenuation with alteplase in mismatch patients. As in EPITHET, we also found a strongly positive relationship between reperfusion and both attenuation of infarct growth and good clinical outcome in the coregistered mismatch group. These results emphasize the concept that selecting patients with PWI/DWI mismatch beyond 3 hours might be a useful approach to extend the time window for thrombolytic therapy. 10, 11 Our findings can now be put in the context of EPITHET, in which there was a borderline significant attenuation in relative infarct growth with alteplase in patients with standard volumetric mismatch. Interestingly, the coregistered mismatch definition appears to be a more sensitive selection criterion, with all measures of infarct growth showing significant attenuation with alteplase in patients included in EPITHET using this approach.
The great advantage of coregistration of PWI and DWI is that it allows a more precise estimate of the spatial relationship between these imaging modalities to occur and, hence, a better understanding of the dynamic nature of the evolving ischemia and reperfusion process. In particular, it becomes clear that portions of the DWI lesions have already reperfused at the time of imaging and, under these circumstances, the volumetric method does underestimate the true proportion of mismatch. 7 This is illustrated in Figure 1A , in which the coregistered MV is greater than the volumetric MV by the amount of the DWI outside volume (the volume of the DWI portion lying outside the PWI lesion). Already reperfused DWI tissue has previously been labeled by reversible acute diffusion lesion already reperfused. 6 This particular region is most likely to recover if reperfusion occurs within 6 hours of symptom onset. Overall, in the current study, MV calculated by the coregistration method was a median of 5 mL (95% CI, 4 -6) larger than that calculated by the volumetric method.
Interestingly, using a higher Tmax threshold instead of Tmax 2-second delay may cause an even larger difference between volumetric and coregistered MV. For example, when using Tmax 6-second threshold, PWI lesion volumes were smaller than those using Tmax 2 seconds (median, 82 vs 162 mL); this made DWI within smaller (10 vs 13 mL) and DWI outside larger (8 vs 5 mL). Although median MV were 48 mL and the prevalence of mismatch was 76% (72/95) by the volumetric method, median MV were 63 mL and the prevalence of mismatch was 85% (81/95) by the coregistration method. In other words, this confirms that the differences between the volumetric and coregistration methods were greater when using Tmax 6 seconds rather than Tmax 2 seconds. It is worth noting that the same central processing and data analysis techniques as the original EPITHET were used, apart from the addition of the coregistration components. There are some limitations to this study. First, some patients were excluded from the analysis because of coregistration failure, mainly attributable to inadequate imaging quality. Therefore, the altered trial results cannot be attributed exclusively to the inclusion of additional patients. There is a constant improvement occurring in the quality of DWI and PWI imaging techniques with software and MR hardware developments. In the clinical trial setting, imaging quality is better-controlled and may allow the support of successful coregistration procedures (including manual adjustment when required), whereas in a clinical setting, volumetric mismatch would seem to be a realistic "fall-back" option in cases in which registration fails. Second, the coregistration method here was only used to select patients and not to assess infarct growth, which requires the presence of follow-up MR images. Coregistration is possible but less reliable at later time points because of the structural changes associated with later infarct volumes, hemorrhagic transformation, and shrinkage. Although it seems likely that automated coregistration software without manual quality control may become a reality in the near future, its clinical use is likely to be restricted to the acute assessment only as it was in the current study. Third, this study was a post hoc analysis and, therefore, does not provide any change in interpretation of the original results of EPITHET. Despite these limitations, this study provided a more ideal mismatch analysis approach for selecting eligible candidates for thrombolytic therapy beyond the 3-hour time window. This suggests that there is a need to develop appropriate software to provide rapid coregistered image analysis.
